Bayer AG (FRA:BAYN) has been given a €124.00 ($144.19) target price by equities researchers at Commerzbank Ag in a report issued on Wednesday. The brokerage presently has a “buy” rating on the healthcare company’s stock. Commerzbank Ag’s target price would suggest a potential upside of 15.08% from the company’s previous close.
BAYN has been the subject of a number of other reports. UBS AG set a €125.00 ($145.35) price objective on shares of Bayer AG and gave the company a “buy” rating in a research note on Tuesday, August 29th. S&P Global set a €126.00 ($146.51) price target on shares of Bayer AG and gave the stock a “buy” rating in a research note on Thursday, October 26th. Independent Research GmbH set a €120.00 ($139.53) price target on shares of Bayer AG and gave the stock a “neutral” rating in a research note on Wednesday, August 23rd. equinet AG set a €118.00 ($137.21) price target on shares of Bayer AG and gave the stock a “buy” rating in a research note on Friday, October 13th. Finally, BNP Paribas set a €130.00 ($151.16) price target on shares of Bayer AG and gave the stock a “buy” rating in a research note on Monday, September 25th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and fourteen have given a buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of €122.33 ($142.25).
Shares of Bayer AG (FRA BAYN) opened at €107.75 ($125.29) on Wednesday. Bayer AG has a 12-month low of €86.06 ($100.07) and a 12-month high of €123.82 ($143.98).
Bayer AG Company Profile
Bayer Aktiengesellschaft operates as a life science company worldwide. The company operates through Pharmaceuticals, Consumer Health, Crop Science, Animal Health, and Covestro segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and womens health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.
Receive News & Ratings for Bayer AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer AG and related companies with MarketBeat.com's FREE daily email newsletter.